Join WIB-Greater Boston as we partner with the AI Drug Discovery & Development (AIDDD) Summit for their second annual Women in AI Lunch. Connect with a community of inspiring professionals for an empowering afternoon featuring trailblazing speakers who are championing women’s leadership across technology, data, and healthcare. Together, we’ll honor the transformative impact of women shaping the future of AI-driven drug discovery and life sciences.

Note: You must be registered for the AIDDD Summit to attend the free luncheon.
WIB members can save 15% on tickets. Log in and click here for a discount code.

Speaker Bios

Kristine Deibler, Head of Molecular AI in AI and Digital Innovation at Novo Nordisk

Kris is leading a global team focused on the development and implementation of AI/ML methods for therapeutic design and optimization across modalities. The MolAI team is actively developing foundation models bespoke to Novo Nordisk to improve molecular representation, prediction of biophysical properties related to developability and potency, and improve our internal ability to apply generative AI effectively in molecular design. Before joining Novo Nordisk, Kris trained as an organic chemist and earned her PhD in organic chemistry from Northwestern University. She pivoted her research focus to computational molecular design during her postdoctoral fellowship with David Baker, where she specialized in designing peptidomimetic GPCR agonists. During this time, she developed innovative computational methods for designing macrocyclic peptides that incorporate non-canonical amino acids. Kris is not only passionate about developing innovative AI methods but is even more driven by the pursuit of discovering impactful therapeutics.

Melissa Landon, Head of Commercial and Business Development, AI, & Automation at MilliporeSigma, Moderator

Melissa is a seasoned life science technology strategist and business leader passionate about bringing technology to bear on challenging problems across drug discovery and development. A nearly 20-year industry veteran who has assumed a variety of roles spanning both science and business, Mel is an entrepreneurial big-picture thinker skilled at honing scientific, business, and commercialization strategies to align with the current and future directions of the market.

Maria-Dorothea Nastke, Director of Oncology at BPGbio

Dr. Nastke is a translational R&D leader with over 12 years of experience advancing oncology and immune-metabolic therapeutics from discovery through IND-enabling development, including both small molecules and biologic drug substances. Currently, she serves as Director of the oncology program at BPGbio, leading scientific staff and overseeing internal program strategy and development in addition to serving as the driver of several strategic external collaborations with both biotech and academic partners. Prior to her post at BPGbio, she was the program lead for multiple differentiated oncology programs at BERG LLC, spearheading interrogation of AI-identified drug targets, dissecting lead molecule mechanism of action, and identifying both pathways and metabolites that could produce actionable biomarkers to further guide drug development. Dr. Nastke earned her PhD in immunology and cell biology from the Eberhard Karls University in Tübingen, Germany, and undertook a research fellowship at the Dana-Farber Cancer Institute in Boston. She has authored numerous publications and presented at numerous conferences in the areas of immuno-oncology and immune-metabolic regulation.

Pricing Information

• Members/Non-Members*: Free with purchase of summit ticket

*Not a Member? Click here to learn about the benefits of a WIB Membership — access to our video library, mentorship groups, and more. 

Please read WIB's Code of Conduct.